CCL2 and COVID-19: This study of a group of non-hospitalized COVID-19 patients reveals a lasting biomarker signature, with elevated levels of eotaxin, monocyte chemoattractant protein-1 (MCP-1), and interferon gamma-induced protein 10 (IP-10) persisting six months after mild infection compared to COVID-negative participants.